PPARA and metabolic disease: Though some PPAR agonists have already been approved for clinical use to treat metabolic diseases, a better understanding of nuclear receptor activation during apoptotic cell clearance may pave the way for the development of novel treatments for infectious, inflammatory, and metabolic diseases.